HSBC Holdings
BHVN

HSBC Holdings’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

HSBC Holdings’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-88,657
Closed -$13.4M – 3336
2022
Q3 		$13.4M Sell
88,657
-242
-0.3% -$35.9K 0.02% 717
2022
Q2 		$12.9M Buy
88,899
+84,342
+1,851% +$10.8M 0.02% 764
2022
Q1 		$545K Sell
4,557
-2,278
-33% -$284K ﹤0.01% 2358
2021
Q4 		$953K Buy
6,835
+3,442
+101% +$438K ﹤0.01% 2084
2021
Q3 		$456K Sell
3,393
-413
-11% -$51.6K ﹤0.01% 2309
2021
Q2 		$369K Buy
+3,806
New +$309K ﹤0.01% 2385

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

HSBC Holdings's BHVN Position: Q4 2022 in Review

HSBC Holdings sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 88,657 shares — an estimated $13.4M sold.

HSBC Holdings first reported a position in BHVN in Q2 2021 and held it in 6 quarters. The position peaked at $13.4M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • HSBC Holdings reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • HSBC Holdings sold 88,657 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $13.4M.
  • HSBC Holdings first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2021 and held it in 6 quarters.
  • HSBC Holdings's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $13.4M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on HSBC Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.